BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

4:25 PM
 | 
Jan 04, 2008
 |  BC Extra  |  Company News

Johnson & Johnson returns rights to TAP technology

ImmunoGen (NASDAQ:IMGN) said Johnson & Johnson (NYSE:JNJ) ended a 2004 deal granting J&J rights to develop and commercialize therapeutics using ImmunoGen's tumor-activated prodrug (TAP) technology. Under a new deal announced Thursday, J&J granted...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >